

Review of: "Personalized (tailored) treatment with antiresorptive drugs (bisphosphonates, denosumab) in patients with bone metastases from solid tumors – A “Pico” document by Rete Oncologica Piemonte-Valle D’Aosta Bone Metastatic Disease Study Group"

Antonio Cortese¹

¹ University of Salerno

Potential competing interests: No potential competing interests to declare.

Thank you for the opportunity of reviewing this paper, it is a very interesting study concerning the possibility of a tailored/precision therapy with antiresorptive drugs in patients with bone metastases from solid tumors.

The aim of this study was to verify the possibility of shifting the therapy from monthly to quarterly such as reducing toxicity, side effects commitments for patients, and costs for NHCS. Conclusions were uncertain about rebound risks, effectiveness after reduction, or changes in a different drug because of insufficient data in the literature.

Very important will be the data collection based on the clinical practice of the Study Group members and the knowledge of the regional real-life problems and issues, besides the literature results.

Another pivotal issue will be the role pre-therapy dental control plays: because of the RAP effect from extractive/invasive dental therapies, their role should be monitored and considered.